TY - JOUR
T1 - Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease
T2 - an observational study
AU - COVID-19 Global Rheumatology Alliance Registry
AU - Izadi, Zara
AU - Gianfrancesco, Milena A.
AU - Schmajuk, Gabriela
AU - Jacobsohn, Lindsay
AU - Katz, Patricia
AU - Rush, Stephanie
AU - Ja, Clairissa
AU - Taylor, Tiffany
AU - Shidara, Kie
AU - Danila, Maria I.
AU - Wysham, Katherine D.
AU - Strangfeld, Anja
AU - Mateus, Elsa F.
AU - Hyrich, Kimme L.
AU - Gossec, Laure
AU - Carmona, Loreto
AU - Lawson-Tovey, Saskia
AU - Kearsley-Fleet, Lianne
AU - Schaefer, Martin
AU - Al-Emadi, Samar
AU - Sparks, Jeffrey A.
AU - Hsu, Tiffany Y.T.
AU - Patel, Naomi J.
AU - Wise, Leanna
AU - Gilbert, Emily
AU - Duarte-García, Alí
AU - Valenzuela-Almada, Maria O.
AU - Ugarte-Gil, Manuel F.
AU - Ljung, Lotta
AU - Scirè, Carlo A.
AU - Carrara, Greta
AU - Hachulla, Eric
AU - Richez, Christophe
AU - Cacoub, Patrice
AU - Thomas, Thierry
AU - Santos, Maria J.
AU - Bernardes, Miguel
AU - Hasseli, Rebecca
AU - Regierer, Anne
AU - Schulze-Koops, Hendrik
AU - Müller-Ladner, Ulf
AU - Pons-Estel, Guillermo
AU - Tanten, Romina
AU - Nieto, Romina E.
AU - Pisoni, Cecilia N.
AU - Tissera, Yohana S.
AU - Xavier, Ricardo
AU - Lopes Marques, Claudia D.
AU - Pileggi, Gecilmara C.S.
AU - Robinson, Philip C.
AU - Machado, Pedro M.
AU - Sirotich, Emily
AU - Liew, Jean W.
AU - Hausmann, Jonathan S.
AU - Sufka, Paul
AU - Grainger, Rebecca
AU - Bhana, Suleman
AU - Gore-Massy, Monique
AU - Wallace, Zachary S.
AU - Yazdany, Jinoos
AU - Dahou, Brahim
AU - Gómez, Gimena
AU - Roberts, Karen
AU - Baez, Roberto M.
AU - Castro Coello, Vanessa V.
AU - Haye Salinas, María J.
AU - Maldonado, Federico N.
AU - Reyes, Alvaro A.
AU - Alle, Gelsomina
AU - Maldonado Ficco, Hernán
AU - Nieto, Romina
AU - Gobbi, Carla
AU - Tissera, Yohana
AU - Pisoni, Cecilia
AU - Paula, Alba
AU - Albiero, Juan A.
AU - Schmid, Maria M.
AU - Cosatti, Micaela
AU - Gamba, Maria J.
AU - Leandro, Carlevaris
AU - Cusa, María A.
AU - German, Noelia
AU - Bellomio, Veronica
AU - Takashima, Lorena
AU - Pera, Mariana
AU - Cogo, Karina
AU - Gálvez Elkin, Maria S.
AU - Medina, María A.
AU - Savio, Veronica
AU - Rojas Tessel, Romina
AU - Alamino, Rodolfo P.
AU - Werner, Marina L.
AU - Ornella, Sofía
AU - Casalla, Luciana
AU - de la Vega, Maria
AU - Severina, María
AU - García, Mercedes
AU - Gonzalez Lucero, Luciana
AU - Romeo, Cecilia
AU - Moyano, Sebastián
AU - Barbich, Tatiana
AU - Bertoli, Ana
AU - Baños, Andrea
AU - Petruzzelli, Sandra
AU - Matellan, Carla
AU - Conti, Silvana
AU - Lazaro, Maria A.
AU - Rodriguez Gil, Gustavo F.
AU - Risueño, Fabian
AU - Quaglia, Maria I.
AU - Scafati, Julia
AU - Cuchiaro, Natalia L.
AU - Rebak, Jonathan E.
AU - Pineda, Susana I.
AU - Calvo, María E.
AU - Picco, Eugenia
AU - Yanzi, Josefina G.
AU - Maid, Pablo
AU - Guaglianone, Debora
AU - Morbiducci, Julieta S.
AU - Porta, Sabrina
AU - Herscovich, Natalia
AU - Velasco Zamora, José L.
AU - Kisluk, Boris
AU - Castaños Menescardi, Maria S.
AU - Gallo, Rosana
AU - Martire, María V.
AU - Maldini, Carla
AU - Goizueta, Cecilia
AU - de la Vega Fernandez, Sabrina S.
AU - Aeschlimann, Carolina
AU - Subils, Gisela
AU - Rath, Eva
AU - Piette, Yves
AU - Devinck, Mieke
AU - Maeyaert, Bea
AU - Machado Ribeiro, Francinne
AU - Euzebio Ribeiro, Sandra L.
AU - Pinheiro, Marcelo
AU - Ibáñez, Sebastián
AU - Chassin Trubert, Anne Marie
AU - Dong, Lingli
AU - Cajas, Lui
AU - Barešić, Marko
AU - Anić, Branimir
AU - Ćulo, Melanie Ivana
AU - Pavelić, Tea A.
AU - Stranski, Kristina K.
AU - Karanovic, Boris
AU - Vencovsky, Jiri
AU - Píchová, Marta
AU - Filkova, Maria
AU - Hamoud, Hesham
AU - Vassilopoulos, Dimitrios
AU - Guzman Melgar, Gabriela M.
AU - So, Ho
AU - Király, Márta
AU - Vojdanian, Mahdi
AU - Balbir Gurman, Alexandra
AU - Abutiban, Fatemah
AU - Zepa, Julija
AU - Bulina, Inita
AU - Bukauskiene, Loreta
AU - Zazueta Montiel, Beatriz E.
AU - Castillo Ortiz, Angel A.
AU - Zamora Tehozol, Erick
AU - Vega Morales, David
AU - Cervántes Rosete, Diana
AU - Martín Nares, Eduardo
AU - Rodriguez Reyna, Tatiana S.
AU - Rull Gabayet, Marina
AU - Alpízar Rodríguez, Deshiré
AU - Irazoque, Fedra
AU - Jimenez, Xochitl
AU - Geurts van Bon, Lenny
AU - Zijlstra, Theo
AU - Hoekstra, Monique
AU - Al Adhoubi, Nasra
AU - Salim, Babur
AU - Giraldo, Enrique
AU - Salinas, Ariel
AU - Nowakowski, Jarosław
AU - Conway, Richard
AU - Flood, Rachael
AU - McCarthy, Geraldine
AU - Felea, Ioana
AU - Filipescu, Ileana
AU - Rednic, Simona
AU - Groseanu, Laura
AU - Tamas, Maria M.
AU - Mlynarikova, Vanda
AU - Skamlova, Martina
AU - Zlnay, Martin
AU - Mičeková, Dagmar
AU - Capova, Lubica
AU - Macejova, Zelmira
AU - Šteňová, Emőke
AU - Raffayova, Helena
AU - Belakova, Gabriela
AU - Parks, Deborah
N1 - Funding Information:
We acknowledge financial support from the American College of Rheumatology and European Alliance of Associations for Rheumatology. The authors were not paid by a pharmaceutical company or other agency to write this article. MAG is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K01 AR070585 and K24 AR074534 [JY]). KDW is supported by the Department of Veterans Affairs and the Rheumatology Research Foundation Scientist Development award. JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K23 AR069688, R03 AR075886, L30 AR066953, P30 AR070253, and P30 AR072577), the Rheumatology Research Foundation (K Supplement Award and R Bridge Award), the Brigham Research Institute, and the R. Bruce and Joan M. Mickey Research Scholar Fund. NJP is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007258). AD-G is supported by grants from the Centers for Disease Control and Prevention and the Rheumatology Research Foundation. RH was supported by the Justus-Liebig University Giessen Clinician Scientist Program in Biomedical Research to work on this registry. JY is supported by grants from the National Institutes of Health (K24 AR074534 and P30 AR070155). The views expressed in this Article are those of the authors and participating members of the COVID-19 Global Rheumatology Alliance, and do not necessarily represent the views of the American College of Rheumatology, the European League Against Rheumatism, the UK National Health Service, the NIHR, the UK Department of Health, or any other organisation.
Funding Information:
We acknowledge financial support from the American College of Rheumatology and European Alliance of Associations for Rheumatology. The authors were not paid by a pharmaceutical company or other agency to write this article. MAG is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K01 AR070585 and K24 AR074534 [JY]). KDW is supported by the Department of Veterans Affairs and the Rheumatology Research Foundation Scientist Development award. JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers K23 AR069688, R03 AR075886, L30 AR066953, P30 AR070253, and P30 AR072577), the Rheumatology Research Foundation (K Supplement Award and R Bridge Award), the Brigham Research Institute, and the R. Bruce and Joan M. Mickey Research Scholar Fund. NJP is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007258). AD-G is supported by grants from the Centers for Disease Control and Prevention and the Rheumatology Research Foundation. RH was supported by the Justus-Liebig University Giessen Clinician Scientist Program in Biomedical Research to work on this registry. JY is supported by grants from the National Institutes of Health (K24 AR074534 and P30 AR070155). The views expressed in this Article are those of the authors and participating members of the COVID-19 Global Rheumatology Alliance, and do not necessarily represent the views of the American College of Rheumatology, the European League Against Rheumatism, the UK National Health Service, the NIHR, the UK Department of Health, or any other organisation.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/9
Y1 - 2022/9
N2 - Background: Differences in the distribution of individual-level clinical risk factors across regions do not fully explain the observed global disparities in COVID-19 outcomes. We aimed to investigate the associations between environmental and societal factors and country-level variations in mortality attributed to COVID-19 among people with rheumatic disease globally. Methods: In this observational study, we derived individual-level data on adults (aged 18–99 years) with rheumatic disease and a confirmed status of their highest COVID-19 severity level from the COVID-19 Global Rheumatology Alliance (GRA) registry, collected between March 12, 2020, and Aug 27, 2021. Environmental and societal factors were obtained from publicly available sources. The primary endpoint was mortality attributed to COVID-19. We used a multivariable logistic regression to evaluate independent associations between environmental and societal factors and death, after controlling for individual-level risk factors. We used a series of nested mixed-effects models to establish whether environmental and societal factors sufficiently explained country-level variations in death. Findings: 14 044 patients from 23 countries were included in the analyses. 10 178 (72·5%) individuals were female and 3866 (27·5%) were male, with a mean age of 54·4 years (SD 15·6). Air pollution (odds ratio 1·10 per 10 μg/m3 [95% CI 1·01–1·17]; p=0·0105), proportion of the population aged 65 years or older (1·19 per 1% increase [1·10–1·30]; p<0·0001), and population mobility (1·03 per 1% increase in number of visits to grocery and pharmacy stores [1·02–1·05]; p<0·0001 and 1·02 per 1% increase in number of visits to workplaces [1·00–1·03]; p=0·032) were independently associated with higher odds of mortality. Number of hospital beds (0·94 per 1-unit increase per 1000 people [0·88–1·00]; p=0·046), human development index (0·65 per 0·1-unit increase [0·44–0·96]; p=0·032), government response stringency (0·83 per 10-unit increase in containment index [0·74–0·93]; p=0·0018), as well as follow-up time (0·78 per month [0·69–0·88]; p<0·0001) were independently associated with lower odds of mortality. These factors sufficiently explained country-level variations in death attributable to COVID-19 (intraclass correlation coefficient 1·2% [0·1–9·5]; p=0·14). Interpretation: Our findings highlight the importance of environmental and societal factors as potential explanations of the observed regional disparities in COVID-19 outcomes among people with rheumatic disease and lay foundation for a new research agenda to address these disparities. Funding: American College of Rheumatology and European Alliance of Associations for Rheumatology.
AB - Background: Differences in the distribution of individual-level clinical risk factors across regions do not fully explain the observed global disparities in COVID-19 outcomes. We aimed to investigate the associations between environmental and societal factors and country-level variations in mortality attributed to COVID-19 among people with rheumatic disease globally. Methods: In this observational study, we derived individual-level data on adults (aged 18–99 years) with rheumatic disease and a confirmed status of their highest COVID-19 severity level from the COVID-19 Global Rheumatology Alliance (GRA) registry, collected between March 12, 2020, and Aug 27, 2021. Environmental and societal factors were obtained from publicly available sources. The primary endpoint was mortality attributed to COVID-19. We used a multivariable logistic regression to evaluate independent associations between environmental and societal factors and death, after controlling for individual-level risk factors. We used a series of nested mixed-effects models to establish whether environmental and societal factors sufficiently explained country-level variations in death. Findings: 14 044 patients from 23 countries were included in the analyses. 10 178 (72·5%) individuals were female and 3866 (27·5%) were male, with a mean age of 54·4 years (SD 15·6). Air pollution (odds ratio 1·10 per 10 μg/m3 [95% CI 1·01–1·17]; p=0·0105), proportion of the population aged 65 years or older (1·19 per 1% increase [1·10–1·30]; p<0·0001), and population mobility (1·03 per 1% increase in number of visits to grocery and pharmacy stores [1·02–1·05]; p<0·0001 and 1·02 per 1% increase in number of visits to workplaces [1·00–1·03]; p=0·032) were independently associated with higher odds of mortality. Number of hospital beds (0·94 per 1-unit increase per 1000 people [0·88–1·00]; p=0·046), human development index (0·65 per 0·1-unit increase [0·44–0·96]; p=0·032), government response stringency (0·83 per 10-unit increase in containment index [0·74–0·93]; p=0·0018), as well as follow-up time (0·78 per month [0·69–0·88]; p<0·0001) were independently associated with lower odds of mortality. These factors sufficiently explained country-level variations in death attributable to COVID-19 (intraclass correlation coefficient 1·2% [0·1–9·5]; p=0·14). Interpretation: Our findings highlight the importance of environmental and societal factors as potential explanations of the observed regional disparities in COVID-19 outcomes among people with rheumatic disease and lay foundation for a new research agenda to address these disparities. Funding: American College of Rheumatology and European Alliance of Associations for Rheumatology.
UR - http://www.scopus.com/inward/record.url?scp=85135909997&partnerID=8YFLogxK
U2 - 10.1016/S2665-9913(22)00192-8
DO - 10.1016/S2665-9913(22)00192-8
M3 - Article
AN - SCOPUS:85135909997
VL - 4
SP - e603-e613
JO - The Lancet Rheumatology
JF - The Lancet Rheumatology
SN - 2665-9913
IS - 9
ER -